Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
Innovate GBM will independently decide whether to pursue any therapeutic asset identified by the project teams.
Innovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development
The sponsorship expands the role of the ai² Division beyond Lōkahi’s own asset discovery efforts. By enabling an external organization to direct project teams toward defined areas of interest, Lōkahi is extending the platform’s analytical reach and demonstrating how the model can augment traditional business development and investment diligence.
“Innovate GBM’s engagement is the next step forward for the ai² PIPELINE as it moves the platform from a company-led initiative to a model that outside organizations can put to work,” said Erik Emerson, Chief Executive Officer of Glucotrack. “This is where the concept begins to scale. We are creating a disciplined way to bring more minds, more perspectives, and more structured evaluation to the search for differentiated therapeutic opportunities.”
“Glioblastoma remains one of the hardest problems in oncology, and too many promising programs have been shelved before they ever reached brain tumor patients,” said Kush Thukral, JD, Co-Executive Director of Innovate GBM. “Lōkahi’s ai² PIPELINE gives us a disciplined, capital-efficient way to search systematically for overlooked brain tumor assets.”
Lōkahi continues to expand ai² Division through a growing network of university collaborations. The Innovate GBM engagement adds a new dimension to that network by connecting student talent and industry expertise directly to the priorities of an external sponsor. Innovate GBM’s project teams will focus on therapeutic assets in glioblastoma and other brain tumors, and Innovate GBM will independently determine whether to pursue any asset identified. Lōkahi believes this sponsor-led model can broaden the platform’s relevance across pharmaceutical companies, biotechnology companies, and investment organizations seeking earlier visibility into differentiated opportunities.
About Lōkahi Therapeutics™
Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit www.lokahithera.com. For more information about the ai² Division and its suite of products, please visit www.ai2equals.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., focuses on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or
About Innovate GBM
Innovate GBM is a 501(c)(3) nonprofit organization dedicated to centralizing and expanding the glioblastoma innovation ecosystem. By bridging biotech companies, research institutions and capital providers, Innovate GBM helps de-risk investment into GBM innovation and move promising research toward patients faster. For more information, please visit www.innovategbm.org.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "anticipate,” "believe,” "can,” “could,” “expect,” “may,” “plan,” “potential,” “seek," and "will" are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack's results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations, or otherwise); the ability of Lōkahi Therapeutics™ to monetize or scale the ai² PIPELINE platform; the ability to attract and retain external sponsors, partners, or collaborators for the ai² PIPELINE; the ability to maintain and expand academic and institutional partnerships; general business and economic conditions; and the additional risk factors described in Glucotrack's filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026. Statements attributed to Innovate GBM reflect the views of Innovate GBM only; Innovate GBM is not responsible for the forward-looking statements of Glucotrack or Lōkahi Therapeutics™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260923982243/en/
Glucotrack
GlucotrackPR@icrinc.com
Lōkahi Therapeutics™
ir@lokahithera.com
Innovate GBM
Kush Thukral, Co-Executive Director
team@innovategbm.org
Source: Lōkahi Therapeutics